Sensus Healthcare (NASDAQ:SRTS) Now Covered by Lake Street Capital

Stock analysts at Lake Street Capital assumed coverage on shares of Sensus Healthcare (NASDAQ:SRTS) in a report released on Friday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $18.00 price target on the stock. Lake Street Capital’s price objective would suggest a potential upside of 132.71% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group lifted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th. HC Wainwright lifted their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded up $0.87 during trading on Friday, hitting $7.74. The company had a trading volume of 172,889 shares, compared to its average volume of 208,548. Sensus Healthcare has a 12 month low of $2.91 and a 12 month high of $9.33. The firm has a market capitalization of $126.78 million, a P/E ratio of 13.62 and a beta of 1.21. The stock has a 50 day simple moving average of $7.51 and a 200 day simple moving average of $6.82.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in shares of Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after acquiring an additional 93,511 shares in the last quarter. Geode Capital Management LLC increased its position in Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after purchasing an additional 11,525 shares during the last quarter. Marshall Wace LLP raised its stake in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares in the last quarter. Ritholtz Wealth Management lifted its position in Sensus Healthcare by 65.3% during the fourth quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after purchasing an additional 20,256 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after buying an additional 13,619 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.